Gelteq (GELS) Current Leases (2023 - 2025)
Gelteq's (GELS) quarterly Current Leases came in at $494084.0 in Q2 2025, up 6114.25% quarter-over-quarter from $7950.8 in Q2 2023.
Gelteq (GELS) Current Leases (2023 - 2025) Analysis & Trends
Gelteq's Current Leases history runs 2 years deep, the most recent figure standing at $494084.0 for Q2 2025.
- On a quarterly basis, Current Leases changed N/A year-over-year to $494084.0 in Q2 2025; TTM through Jun 2025 was $494084.0, a N/A change from a year earlier, with the FY2025 full-year figure at $494084.0, changed N/A from the prior year.
- Current Leases climbed to $494084.0 in Q2 2025 per GELS's latest filing, from $7950.8 in the prior quarter.
- Across five years, Current Leases topped out at $494084.0 in Q2 2025 and bottomed at $7950.8 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Gelteq | 740.00 | -47,821.64 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 494,083.97 |
| Jun 30, 2023 | 7,950.82 |